CN107098973A - St2l拮抗剂及使用方法 - Google Patents

St2l拮抗剂及使用方法 Download PDF

Info

Publication number
CN107098973A
CN107098973A CN201710188519.0A CN201710188519A CN107098973A CN 107098973 A CN107098973 A CN 107098973A CN 201710188519 A CN201710188519 A CN 201710188519A CN 107098973 A CN107098973 A CN 107098973A
Authority
CN
China
Prior art keywords
seq
ser
st2l
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710188519.0A
Other languages
English (en)
Chinese (zh)
Inventor
K.达菲
C.希利
R.拉姆布
R.马拉维亚
M.普拉塔
N.富索夫
J.罗
M.纳索
M.托内塔
J.惠勒
S-J.吴
L.哈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CN107098973A publication Critical patent/CN107098973A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • A61K38/012Hydrolysed proteins; Derivatives thereof from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Catching Or Destruction (AREA)
CN201710188519.0A 2012-04-30 2013-04-29 St2l拮抗剂及使用方法 Pending CN107098973A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261640407P 2012-04-30 2012-04-30
US201261640238P 2012-04-30 2012-04-30
US61/640238 2012-04-30
US61/640407 2012-04-30
US13/798,226 US9212227B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
US13/798204 2013-03-13
US13/798,204 US9090694B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists
US13/798226 2013-03-13
CN201380035058.3A CN104411333B (zh) 2012-04-30 2013-04-29 St2l拮抗剂及使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380035058.3A Division CN104411333B (zh) 2012-04-30 2013-04-29 St2l拮抗剂及使用方法

Publications (1)

Publication Number Publication Date
CN107098973A true CN107098973A (zh) 2017-08-29

Family

ID=49477497

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710188519.0A Pending CN107098973A (zh) 2012-04-30 2013-04-29 St2l拮抗剂及使用方法
CN201380035058.3A Expired - Fee Related CN104411333B (zh) 2012-04-30 2013-04-29 St2l拮抗剂及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380035058.3A Expired - Fee Related CN104411333B (zh) 2012-04-30 2013-04-29 St2l拮抗剂及使用方法

Country Status (37)

Country Link
US (4) US9212227B2 (enExample)
EP (2) EP2844292B1 (enExample)
JP (3) JP6283354B2 (enExample)
KR (2) KR102147140B1 (enExample)
CN (2) CN107098973A (enExample)
AR (1) AR090909A1 (enExample)
AU (2) AU2013256645B2 (enExample)
BR (1) BR112014027165A2 (enExample)
CA (1) CA2871948C (enExample)
CL (1) CL2014002955A1 (enExample)
CO (1) CO7240389A2 (enExample)
CR (1) CR20140488A (enExample)
CY (1) CY1122308T1 (enExample)
DK (1) DK2844292T3 (enExample)
EA (2) EA201891264A3 (enExample)
EC (1) ECSP14025178A (enExample)
ES (1) ES2755094T3 (enExample)
HR (1) HRP20191884T1 (enExample)
HU (1) HUE045864T2 (enExample)
IL (2) IL235401B (enExample)
LT (1) LT2844292T (enExample)
MX (2) MX358134B (enExample)
MY (1) MY166062A (enExample)
NI (1) NI201400125A (enExample)
NZ (3) NZ702136A (enExample)
PE (1) PE20150641A1 (enExample)
PH (2) PH12014502435A1 (enExample)
PL (1) PL2844292T3 (enExample)
PT (1) PT2844292T (enExample)
RS (1) RS59511B1 (enExample)
SG (2) SG10201608525SA (enExample)
SI (1) SI2844292T1 (enExample)
SM (1) SMT201900639T1 (enExample)
TW (3) TWI700299B (enExample)
UA (1) UA118336C2 (enExample)
UY (1) UY34774A (enExample)
WO (1) WO2013165894A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113286814A (zh) * 2018-10-31 2021-08-20 德里尼亚公司 多价调节性t细胞调节子

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2609043T3 (es) 2009-11-30 2017-04-18 Janssen Biotech, Inc. Anticuerpos mutantes Fc con funciones de efecto abladas
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9637535B2 (en) 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
WO2015106080A2 (en) 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)
EP3134120B1 (en) 2014-04-21 2024-01-24 The Children's Hospital of Philadelphia Compositions and methods for treating cytokine-related disorders
US9631024B2 (en) 2014-06-23 2017-04-25 Bionomics, Inc. Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors
US20160168640A1 (en) 2014-11-10 2016-06-16 Genentech, Inc. Therapeutic and diagnostic methods for il-33-mediated disorders
MX2017006094A (es) 2014-11-10 2017-07-19 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos.
CA2978431C (en) 2015-03-02 2023-10-24 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
CA2990305A1 (en) * 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
MX2018008732A (es) * 2016-01-14 2018-12-06 Anaptysbio Inc Inhibicion de la reaccion alergica usando un inhibidor de il-33.
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US20190225682A1 (en) * 2016-09-02 2019-07-25 180 Therapeutics Lp Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
EP3506920A4 (en) * 2016-09-02 2020-05-27 180 Therapeutics LP METHOD FOR TREATING SYSTEMIC FIBROTIC DISEASES WITH A BISPECIFIC IL-33 / TNF ANTIBODY
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
TWI778018B (zh) 2017-02-10 2022-09-21 美商建南德克公司 抗類胰蛋白酶抗體、其組合物及其用途
JP7205995B2 (ja) * 2017-03-29 2023-01-17 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 共刺激性tnf受容体に対する二重特異性抗原結合分子
EP3957752B1 (en) 2017-04-13 2025-08-20 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
WO2019122052A2 (en) 2017-12-21 2019-06-27 F. Hoffmann-La Roche Ag Antibodies binding to hla-a2/wt1
WO2019157358A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
IL277890B2 (en) 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantifying il-33
KR102353568B1 (ko) 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN110045131B (zh) * 2019-06-14 2019-09-03 迈威(上海)生物科技有限公司 用于测定人il-33/st2通路抑制剂的生物学活性的方法
CA3158323A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Methods of using il-33 antagonists
KR20220092927A (ko) 2019-11-04 2022-07-04 메디뮨 리미티드 신장 장애를 치료하기 위한 항 il-33 치료제
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
BR112022019937A2 (pt) 2020-04-06 2022-12-13 Medimmune Ltd Tratamento de síndrome do desconforto respiratório agudo com antagonistas de ligação de eixo de il-33
WO2021228091A1 (zh) 2020-05-12 2021-11-18 正大天晴药业集团股份有限公司 St2抗原结合蛋白
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
TW202322850A (zh) * 2021-08-05 2023-06-16 美商美國禮來大藥廠 抗體最佳化
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
JP2025508835A (ja) * 2022-02-24 2025-04-10 シノマブ バイオサイエンス リミテッド アラーミンに対する二重特異性結合タンパク質およびその使用
CN115838425B (zh) * 2022-08-31 2024-06-18 首都医科大学 一种靶向血管紧张素ii 1型受体细胞外第二环的抗体及其应用
AU2023345467A1 (en) 2022-09-21 2025-05-08 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use
CN119841936B (zh) * 2024-12-30 2025-09-30 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 抗非洲猪瘟病毒p72蛋白中和性单克隆抗体5d2及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999034217A1 (en) * 1997-12-24 1999-07-08 The University Court Of The University Of Glasgow Reagents specific for st2l and uses therefor
WO2001021641A1 (en) * 1999-09-24 2001-03-29 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis and treatment of immune disorders
US20100247442A1 (en) * 2009-03-31 2010-09-30 Adam Cotty Macaca fascicularis ST2L

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
ATE399855T1 (de) 1996-10-10 2008-07-15 Invitrogen Corp Tierzellkulturmedium mit pflanzlichen nährstoffen
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
WO2001070817A1 (en) 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
ES2649037T3 (es) * 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US6649055B1 (en) 2002-05-07 2003-11-18 The United States Of America As Represented By The United States Department Of Energy Pump station for radioactive waste water
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
EP1718602A4 (en) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd THERAPEUTIC AND CARRIER MOLECULES
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2006055347A2 (en) 2004-11-15 2006-05-26 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
PL2059535T3 (pl) 2006-08-18 2014-04-30 Novartis Ag Przeciwciało specyficzne względem PRLR i jego zastosowanie
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
CA2686683A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc Il-33 in inflammatory disease
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
CA2710373A1 (en) 2007-12-19 2009-07-09 Ping Tsui Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
EP2899209A1 (en) 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
US8817596B2 (en) 2009-01-09 2014-08-26 Futurewei Technologies, Inc. Protecting ingress and egress of a label switched path
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
ES2609043T3 (es) * 2009-11-30 2017-04-18 Janssen Biotech, Inc. Anticuerpos mutantes Fc con funciones de efecto abladas
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
CN103097416B (zh) 2010-03-30 2015-09-09 詹森生物科技公司 人源化il-25抗体
HRP20160461T1 (hr) 2010-04-09 2016-06-17 Critical Care Diagnostics, Inc. Solubilna humana st-2 antitijela i eseji
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
JP6126991B2 (ja) 2010-09-27 2017-05-10 ヤンセン バイオテツク,インコーポレーテツド ヒトii型コラーゲンに結合する抗体
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US8785153B2 (en) 2011-02-23 2014-07-22 Hoffmann-La Roche, Inc. Antibodies against human IL33R and uses thereof
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999034217A1 (en) * 1997-12-24 1999-07-08 The University Court Of The University Of Glasgow Reagents specific for st2l and uses therefor
WO2001021641A1 (en) * 1999-09-24 2001-03-29 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis and treatment of immune disorders
US20100247442A1 (en) * 2009-03-31 2010-09-30 Adam Cotty Macaca fascicularis ST2L

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEMANTH RAMAPRAKASH: "Targeting ST2L Potentiates CpG-Mediated Therapeutic Effects in a Chronic Fungal Asthma Model", 《THE AMERICAN JOURNAL OF PATHOLOGY》 *
KENJI KUROIWA: "Construction of ELISA System to Quantify Human ST2 Protein in Sera of Patients", 《HYBRIDOMA》 *
NATALIE FURSOV: "Generation and Characterization of Rat Anti-mouse ST2L Monoclonal Antibodies", 《HYBRIDOMA》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113286814A (zh) * 2018-10-31 2021-08-20 德里尼亚公司 多价调节性t细胞调节子

Also Published As

Publication number Publication date
EP2844292B1 (en) 2019-08-21
JP2019162136A (ja) 2019-09-26
IL235401A0 (en) 2014-12-31
JP2018064560A (ja) 2018-04-26
TWI589588B (zh) 2017-07-01
CY1122308T1 (el) 2021-01-27
TWI700299B (zh) 2020-08-01
EA201491996A1 (ru) 2015-04-30
EP2844292A2 (en) 2015-03-11
EA201891264A2 (ru) 2018-11-30
AU2013256645B2 (en) 2017-06-08
MX2018009430A (es) 2020-09-02
US9212227B2 (en) 2015-12-15
TWI687440B (zh) 2020-03-11
PT2844292T (pt) 2019-11-26
IL254569B (en) 2020-10-29
UA118336C2 (uk) 2019-01-10
WO2013165894A3 (en) 2014-03-27
ES2755094T3 (es) 2020-04-21
KR20200037886A (ko) 2020-04-09
IL254569A0 (en) 2017-11-30
SG10201608525SA (en) 2016-12-29
EP2844292A4 (en) 2016-05-25
JP2015516817A (ja) 2015-06-18
NZ740221A (en) 2019-11-29
PL2844292T3 (pl) 2020-03-31
SMT201900639T1 (it) 2020-01-14
CA2871948C (en) 2020-09-08
ECSP14025178A (es) 2015-08-31
JP6622274B2 (ja) 2019-12-18
CR20140488A (es) 2015-01-12
IL235401B (en) 2020-10-29
PH12014502435A1 (en) 2015-01-12
RS59511B1 (sr) 2019-12-31
MY166062A (en) 2018-05-22
HUE045864T2 (hu) 2020-01-28
MX2014013200A (es) 2014-12-08
US9951137B2 (en) 2018-04-24
US20130287777A1 (en) 2013-10-31
TW202019969A (zh) 2020-06-01
DK2844292T3 (da) 2019-10-21
NZ729913A (en) 2018-07-27
WO2013165894A2 (en) 2013-11-07
NI201400125A (es) 2016-11-30
US20190062439A1 (en) 2019-02-28
CO7240389A2 (es) 2015-04-17
AU2017202610B2 (en) 2019-06-13
AU2013256645A1 (en) 2014-11-13
CL2014002955A1 (es) 2015-01-16
LT2844292T (lt) 2019-11-25
NZ702136A (en) 2017-03-31
AR090909A1 (es) 2014-12-17
UY34774A (es) 2013-11-29
AU2017202610A1 (en) 2017-05-11
HK1208182A1 (en) 2016-02-26
CN104411333B (zh) 2017-04-26
EA031047B1 (ru) 2018-11-30
CN104411333A (zh) 2015-03-11
BR112014027165A2 (pt) 2017-07-18
SI2844292T1 (sl) 2020-02-28
TW201730216A (zh) 2017-09-01
US10450377B2 (en) 2019-10-22
KR20150008152A (ko) 2015-01-21
US20170066831A1 (en) 2017-03-09
PE20150641A1 (es) 2015-05-11
TW201345923A (zh) 2013-11-16
AU2017202610B9 (en) 2019-06-20
EA201891264A3 (ru) 2019-02-28
US20130336980A1 (en) 2013-12-19
HRP20191884T1 (hr) 2020-02-07
SG11201407028WA (en) 2015-01-29
KR102147140B1 (ko) 2020-08-25
CA2871948A1 (en) 2013-11-07
EP3597219A1 (en) 2020-01-22
JP6283354B2 (ja) 2018-02-21
MX358134B (es) 2018-08-06
PH12018501839A1 (en) 2020-09-14
US9090694B2 (en) 2015-07-28

Similar Documents

Publication Publication Date Title
CN104411333B (zh) St2l拮抗剂及使用方法
CN102905727B (zh) Il-17a拮抗剂
JP6556742B2 (ja) 抗ccl17抗体
CN103328508A (zh) 针对制癌蛋白m(osm)的抗原结合蛋白
KR102709785B1 (ko) Il-5 항체, 이의 항원 결합 단편 및 이의 의학적 적용
KR20230087552A (ko) Cd45를 다량체화하는 결합 분자
HK40021074A (en) St2l antagonists and methods of use
HK1236206A1 (en) St2l antagonists and methods of use
HK1208182B (en) St2l antagonists and methods of use
HK40088986A (zh) 多聚化cd45的结合分子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1236206

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170829

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1236206

Country of ref document: HK